Related Experiment Video
Updated: Jan 6, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Neurodevelopmental disorders among term infants exposed to antenatal corticosteroids during pregnancy: a
Nir Melamed1, Elizabeth Asztalos2, Kellie Murphy3
1Obstetrics and Gynecology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada nir.melamed@sunnybrook.ca.
Insights
Antenatal corticosteroids (ACS) exposure in term infants is associated with increased healthcare use for neurodevelopmental issues. This study found higher rates of neurocognitive and neurosensory disorders in ACS-exposed children.
Area of Science:
- Perinatal medicine
- Developmental pediatrics
- Public health
Background:
- Antenatal corticosteroids (ACS) are increasingly used to improve fetal lung maturity.
- Long-term safety concerns regarding neurodevelopmental outcomes persist despite ACS benefits.
Purpose of the Study:
- To assess the association between antenatal corticosteroid exposure and neurodevelopmental problems in term infants.
- To compare the likelihood of neurodevelopmental issues in ACS-exposed versus non-exposed infants.
Main Methods:
- Retrospective population-based cohort study of 529,205 live singleton term infants in Ontario, Canada (2006-2011).
- Follow-up duration averaged 7.8 years.
- Neurodevelopmental problems were identified using diagnostic codes for audiometry, visual testing, or suspected neurocognitive disorders.
Main Results:
- Infants exposed to ACS showed a higher cumulative rate of neurodevelopmental problems by age 5 (61.7% vs 57.8%, p<0.001).
- Increased healthcare utilization was observed for audiometry testing (15.3% vs 12.7%), visual testing (45.4% vs 43.5%), and suspected neurocognitive disorders (25.8% vs 21.6%) in the ACS-exposed group.
- The number needed to harm for the composite outcome was 25, indicating a small but significant increase in risk.
Conclusions:
- Exposure to antenatal corticosteroids in term infants is associated with increased healthcare utilization for suspected neurocognitive and neurosensory disorders in childhood.
- These findings highlight a potential long-term neurodevelopmental consequence of ACS exposure.
- Further research may be warranted to understand the mechanisms and implications of this association.
Objective:
An increasing proportion of fetuses are exposed to antenatal corticosteroids (ACS). Despite their immediate beneficial effects, the long-term safety of ACS has been an ongoing source of concern. In the current study, we assessed the likelihood of neurodevelopmental problems among term infants exposed to ACS earlier in pregnancy compared with non-exposed term infants.
Design:
Retrospective cohort study (2006-2011). Median duration of follow-up was 7.8 (IQR 6.4-9.2) years.
Setting:
Population-based study, Ontario, Canada.
Participants:
All live singleton infants born at term (≥370/7 weeks gestation) (n=529 205).
Exposure:
ACS during pregnancy.
Primary And Secondary Outcome Measures:
A composite of diagnostic or billing codes reflecting proven or suspected neurodevelopmental problems during childhood including audiometry testing, visual testing or physician service claim with a diagnosis code related to a suspected neurocognitive disorder.
Results:
At 5 years of age, the cumulative rate for the primary outcome was higher among infants exposed to ACS compared with non-exposed infants: 61.7% (3346/5423) vs 57.8% (302 520/523 782), respectively (p<0.001; number needed to harm (NNH)=25, 95% CI 19 to 38; adjusted HR (aHR) 1.12, 95% CI 1.08 to 1.16). Similar findings were observed for each of the individual components of the primary outcome: 15.3% vs 12.7% for audiometry testing (p<0.001; NNH=39, 95% CI 29 to 63; aHR 1.18, 95% CI 1.11 to 1.25); 45.4% vs 43.5% for visual testing (p=0.006; NNH=54, 95% CI 31 to 200; aHR 1.08, 95% CI 1.04 to 1.12) and 25.8% vs 21.6% for suspected neurocognitive disorder (p<0.001; NNH=24, 95% CI 19 to 33; aHR 1.16, 95% CI 1.10 to 1.21).
Conclusions:
We found an association among term infants between exposure to ACS during pregnancy and healthcare utilisation during childhood related to suspected neurocognitive and neurosensory disorders.
More Related Videos
Related Concept Videos
Teratogenicity
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Adrenal Gland Disorders
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Factors Affecting Drug Response: Overview

